Cargando…

Improvement of Long COVID symptoms over one year

IMPORTANCE: Early and accurate diagnosis and treatment of Long COVID, clinically known as post-acute sequelae of COVID-19 (PASC), may mitigate progression to chronic diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our objective was to determine the utility of the DePaul...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Carlos R., Jason, Leonard A., Unutmaz, Derya, Bateman, Lucinda, Vernon, Suzanne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868805/
https://www.ncbi.nlm.nih.gov/pubmed/36698810
http://dx.doi.org/10.3389/fmed.2022.1065620
_version_ 1784876625882513408
author Oliveira, Carlos R.
Jason, Leonard A.
Unutmaz, Derya
Bateman, Lucinda
Vernon, Suzanne D.
author_facet Oliveira, Carlos R.
Jason, Leonard A.
Unutmaz, Derya
Bateman, Lucinda
Vernon, Suzanne D.
author_sort Oliveira, Carlos R.
collection PubMed
description IMPORTANCE: Early and accurate diagnosis and treatment of Long COVID, clinically known as post-acute sequelae of COVID-19 (PASC), may mitigate progression to chronic diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our objective was to determine the utility of the DePaul Symptom Questionnaire (DSQ) to assess the frequency and severity of common symptoms of ME/CFS, to diagnose and monitor symptoms in patients with PASC. METHODS: This prospective, observational cohort study enrolled 185 people that included 34 patients with PASC that had positive COVID-19 test and persistent symptoms of >3 months and 151 patients diagnosed with ME/CFS. PASC patients were followed over 1 year and responded to the DSQ at baseline and 12 months. ME/CFS patients responded to the DSQ at baseline and 1 year later. Changes in symptoms over time were analyzed using a fixed-effects model to compute difference-in-differences estimates between baseline and 1-year follow-up assessments. PARTICIPANTS: Patients were defined as having PASC if they had a previous positive COVID-19 test, were experiencing symptoms of fatigue, post-exertional malaise, or other unwellness for at least 3 months, were not hospitalized for COVID-19, had no documented major medical or psychiatric diseases prior to COVID-19, and had no other active and untreated disease processes that could explain their symptoms. PASC patients were recruited in 2021. ME/CFS patients were recruited in 2017. RESULTS: At baseline, patients with PASC had similar symptom severity and frequency as patients with ME/CFS and satisfied ME/CFS diagnostic criteria. ME/CFS patients experienced significantly more severe unrefreshing sleep and flu-like symptoms. Five symptoms improved significantly over the course of 1 year for PASC patients including fatigue, post-exertional malaise, brain fog, irritable bowel symptoms and feeling unsteady. In contrast, there were no significant symptom improvements for ME/CFS patients. CONCLUSION AND RELEVANCE: There were considerable similarities between patients with PASC and ME/CFS at baseline. However, symptoms improved for PASC patients over the course of a year but not for ME/CFS patients. PASC patients with significant symptom improvement no longer met ME/CFS clinical diagnostic criteria. These findings indicate that the DSQ can be used to reliably assess and monitor PASC symptoms.
format Online
Article
Text
id pubmed-9868805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98688052023-01-24 Improvement of Long COVID symptoms over one year Oliveira, Carlos R. Jason, Leonard A. Unutmaz, Derya Bateman, Lucinda Vernon, Suzanne D. Front Med (Lausanne) Medicine IMPORTANCE: Early and accurate diagnosis and treatment of Long COVID, clinically known as post-acute sequelae of COVID-19 (PASC), may mitigate progression to chronic diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our objective was to determine the utility of the DePaul Symptom Questionnaire (DSQ) to assess the frequency and severity of common symptoms of ME/CFS, to diagnose and monitor symptoms in patients with PASC. METHODS: This prospective, observational cohort study enrolled 185 people that included 34 patients with PASC that had positive COVID-19 test and persistent symptoms of >3 months and 151 patients diagnosed with ME/CFS. PASC patients were followed over 1 year and responded to the DSQ at baseline and 12 months. ME/CFS patients responded to the DSQ at baseline and 1 year later. Changes in symptoms over time were analyzed using a fixed-effects model to compute difference-in-differences estimates between baseline and 1-year follow-up assessments. PARTICIPANTS: Patients were defined as having PASC if they had a previous positive COVID-19 test, were experiencing symptoms of fatigue, post-exertional malaise, or other unwellness for at least 3 months, were not hospitalized for COVID-19, had no documented major medical or psychiatric diseases prior to COVID-19, and had no other active and untreated disease processes that could explain their symptoms. PASC patients were recruited in 2021. ME/CFS patients were recruited in 2017. RESULTS: At baseline, patients with PASC had similar symptom severity and frequency as patients with ME/CFS and satisfied ME/CFS diagnostic criteria. ME/CFS patients experienced significantly more severe unrefreshing sleep and flu-like symptoms. Five symptoms improved significantly over the course of 1 year for PASC patients including fatigue, post-exertional malaise, brain fog, irritable bowel symptoms and feeling unsteady. In contrast, there were no significant symptom improvements for ME/CFS patients. CONCLUSION AND RELEVANCE: There were considerable similarities between patients with PASC and ME/CFS at baseline. However, symptoms improved for PASC patients over the course of a year but not for ME/CFS patients. PASC patients with significant symptom improvement no longer met ME/CFS clinical diagnostic criteria. These findings indicate that the DSQ can be used to reliably assess and monitor PASC symptoms. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9868805/ /pubmed/36698810 http://dx.doi.org/10.3389/fmed.2022.1065620 Text en Copyright © 2023 Oliveira, Jason, Unutmaz, Bateman and Vernon. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Oliveira, Carlos R.
Jason, Leonard A.
Unutmaz, Derya
Bateman, Lucinda
Vernon, Suzanne D.
Improvement of Long COVID symptoms over one year
title Improvement of Long COVID symptoms over one year
title_full Improvement of Long COVID symptoms over one year
title_fullStr Improvement of Long COVID symptoms over one year
title_full_unstemmed Improvement of Long COVID symptoms over one year
title_short Improvement of Long COVID symptoms over one year
title_sort improvement of long covid symptoms over one year
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868805/
https://www.ncbi.nlm.nih.gov/pubmed/36698810
http://dx.doi.org/10.3389/fmed.2022.1065620
work_keys_str_mv AT oliveiracarlosr improvementoflongcovidsymptomsoveroneyear
AT jasonleonarda improvementoflongcovidsymptomsoveroneyear
AT unutmazderya improvementoflongcovidsymptomsoveroneyear
AT batemanlucinda improvementoflongcovidsymptomsoveroneyear
AT vernonsuzanned improvementoflongcovidsymptomsoveroneyear